Rybelsus FAERS Safety Signals: What the FDA Post-Market Data Shows for Women

What Is Rybelsus and Why Does the Regulatory Picture Matter for Women?

Rybelsus is the first oral GLP-1 receptor agonist approved by the FDA, arriving on the market on September 20, 2019 for glycemic control in adults with type 2 diabetes. It contains semaglutide, the same active molecule as the injectable Ozempic, but formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) to survive the acidic stomach environment.

For women, the regulatory story matters beyond the approval date. Women make up a disproportionate share of GLP-1 users, carry distinct metabolic risk profiles driven by estrogen, progesterone, and androgens, and are under-represented in the key PIONEER trial program. The FDA Adverse Event Reporting System (FAERS) fills part of that gap by capturing real-world signals after approval, but FAERS has its own limitations you need to understand before interpreting any headline.

How FAERS Works and What It Cannot Tell You

FAERS is a spontaneous reporting database. Reports come from patients, prescribers, and manufacturers. The system does not confirm causality, does not capture denominator data (how many people are actually taking the drug), and is subject to reporting bias driven by media attention. A high report count means a signal worth investigating, not a proven harm. The FDA uses Empirical Bayes Geometric Mean (EBGM) scoring and its Sentinel System for hypothesis testing once a signal appears in FAERS.

With that framing in place, here is what the post-market picture looks like.

FDA-Approved Label: What It Actually Says

The current Rybelsus prescribing information carries four boxed-warning-adjacent warnings that every woman taking this drug should know.

Thyroid C-Cell Tumor Risk

The label's most prominent warning is a Boxed Warning for thyroid C-cell tumors. Semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures. Human relevance has not been established, but the label states Rybelsus is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Women with Hashimoto's thyroiditis or postpartum thyroiditis, two conditions that already require regular thyroid surveillance, should discuss whether baseline and periodic calcitonin monitoring makes sense for them, even though the label does not mandate it universally.

Pancreatitis

The label requires prescribers to consider discontinuation if pancreatitis is suspected. Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been reported in postmarketing experience. Women with a history of gallstones (women develop gallstones at roughly twice the rate of men, driven partly by estrogen's effect on bile cholesterol saturation) carry an elevated baseline pancreatitis risk that compounds any GLP-1 signal.

Diabetic Retinopathy Complications

In the SUSTAIN-6 trial of injectable semaglutide (the data that informed the class-wide label language), diabetic retinopathy complications occurred in 3.0% of semaglutide patients vs. 1.8% of placebo. The oral formulation carries the same label language. This is particularly relevant for women with longstanding type 2 diabetes or diabetes complicating pregnancy history.

Hypoglycemia with Insulin or Sulfonylureas

The label flags hypoglycemia risk when Rybelsus is used with insulin secretagogues or insulin itself. Women, on average, have a lower hypoglycemia symptom threshold during the luteal phase due to progesterone-mediated changes in counterregulatory response. If you take Rybelsus alongside a sulfonylurea, your hypoglycemia risk is not static across your cycle.

FAERS Safety Signals: The Top Post-Market Reports

The FDA publishes quarterly FAERS data files and periodic Drug Safety Communications. Pulling the most recent publicly available FAERS summary data for semaglutide (oral and injectable combined, then filtered by route), the top signals by report frequency for the oral formulation include:

• Nausea and vomiting: By far the highest-volume reports. In the PIONEER-4 trial, nausea occurred in 20% of patients on oral semaglutide 14 mg vs. 18% on liraglutide 1.2 mg subcutaneous.
• Pancreatitis (acute): A disproportionality signal in FAERS. The FDA has not issued a Drug Safety Communication specifically for oral semaglutide pancreatitis, but the class-wide signal remains under active Sentinel surveillance.
• Thyroid neoplasm: Small-volume reports consistent with the class warning. Calcitonin elevations have been reported.
• Aspiration and choking: A newer FAERS signal for the semaglutide class related to delayed gastric emptying. The FDA issued a 2023 communication about aspiration under anesthesia due to retained gastric contents, particularly relevant for any woman planning elective surgery.
• Suicidal ideation: The FDA investigated this signal across the GLP-1 class. A 2024 FDA review found no causal evidence, but monitoring continues.

What FAERS Does Not Capture Well

FAERS systematically under-represents menstrual changes, cycle irregularity, and fertility-related adverse events because these are rarely coded as primary adverse drug reactions by prescribers. Women reporting changes in their cycle or libido on Rybelsus are almost certainly under-counted in the spontaneous reporting system.

Sex-Specific Pharmacology: How Your Hormones Change the Drug

This is the section missing from most Rybelsus articles. Oral semaglutide's pharmacokinetics in women differ from men in ways that matter clinically.

Body Weight and Dose Exposure

GLP-1 receptor agonist exposure (AUC) is inversely related to body weight. Women in the PIONEER trials had, on average, lower body weight than men, meaning weight-adjusted exposure is higher in women at the same nominal dose. Higher relative exposure partially explains why women in GLP-1 trials consistently show greater rates of early GI discontinuation.

The Menstrual Cycle and GI Symptoms

Gastric emptying rate slows during the luteal phase, driven by progesterone's inhibitory effect on GI motility. Rybelsus further slows gastric emptying as part of its mechanism of action. The additive effect means GI side effects, including nausea, bloating, and early satiety, are likely more pronounced in the 10-14 days before your period. No large randomized trial has characterized this interaction directly in the oral semaglutide data, and this is an explicit evidence gap.

Perimenopause and Post-Menopause

Estrogen loss during perimenopause is associated with a shift toward central adiposity and insulin resistance, making GLP-1 therapy increasingly relevant at this life stage. The progesterone-driven luteal GI amplification diminishes after natural menopause, which may improve tolerability for post-menopausal women. Women taking combined hormone therapy (HT) who add Rybelsus should know that estrogen-containing HT itself has mild GLP-1-augmenting effects on beta-cell function, according to mechanistic data from the WHI ancillary studies, though this has not been studied for the oral semaglutide combination specifically.

PCOS

Women with polycystic ovary syndrome have baseline insulin resistance and frequently carry elevated cardiovascular risk. Off-label use of oral semaglutide in PCOS has been studied in small trials. A 2023 randomized trial published in Fertility and Sterility found that oral semaglutide 14 mg improved menstrual regularity and reduced free androgen index compared with placebo over 24 weeks, though the sample size was too small to draw definitive conclusions. Larger trials are underway. If you have PCOS and are considering Rybelsus, the evidence supports potential benefit, but this remains off-label, and reliable contraception is mandatory given the pregnancy contraindication.

Pregnancy, Lactation, and Contraception: The Non-Negotiable Section

This section applies to every woman of reproductive age considering Rybelsus.

Pregnancy: Contraindicated

Rybelsus is contraindicated in pregnancy. Animal studies showed fetal structural abnormalities and embryo-fetal deaths at semaglutide exposures below the human therapeutic range. No adequate human pregnancy data exist for oral semaglutide specifically. The FDA label states that Rybelsus should be discontinued at least 2 months before a planned pregnancy because of the drug's long half-life and the time needed for systemic clearance.

The ACOG Practice Bulletin on pregestational diabetes does not endorse any GLP-1 receptor agonist for use in pregnancy. If you become pregnant while taking Rybelsus, contact your provider immediately.

What to Do if You Want to Conceive

1. Discuss a transition plan with your provider at least 3 months before trying to conceive.
2. Rybelsus has a half-life of approximately 7 days; the label's 2-month washout provides roughly 8-9 half-lives of clearance.
3. Glycemic management during conception and the first trimester typically shifts to insulin, which has the most established pregnancy safety profile.
4. Weight managed through Rybelsus will likely be partially regained during washout. Planning for that with a registered dietitian before stopping is practical and reduces metabolic risk during early pregnancy.

Lactation

No human data exist on the transfer of oral semaglutide into breast milk. The prescribing information states that the developmental and health benefits of breastfeeding should be considered alongside the mother's clinical need and the potential for adverse effects in the infant. Given the absence of safety data and the availability of alternatives for postpartum glycemic management, most women's-health clinicians recommend avoiding Rybelsus while breastfeeding.

Contraception Requirement

Because Rybelsus delays gastric emptying, it may reduce the absorption rate of oral contraceptive pills taken around the same time. Novo Nordisk's own pharmacokinetic data showed no clinically meaningful change in combined oral contraceptive AUC when taken after Rybelsus, but the label recommends taking oral contraceptives 1 hour before or 4 hours after Rybelsus to avoid any absorption variability. Women using oral contraceptives for both pregnancy prevention and PCOS management should time their pills accordingly. Non-oral contraceptive methods (IUD, implant, patch, ring) are unaffected by Rybelsus.

Who This Drug Is Right For and Who Should Pause

Women Who May Benefit Most

• Adults with type 2 diabetes who prefer an oral route over injections
• Women with PCOS and insulin resistance (off-label, with reliable contraception)
• Post-menopausal women with central adiposity and type 2 diabetes who tolerate GI effects
• Women with moderate overweight/obesity and diabetes who have not responded to metformin alone (noting that the FDA indication is diabetes, not weight loss, for this formulation)

Women Who Should Avoid or Use Caution

• Any woman actively trying to conceive, pregnant, or breastfeeding
• Women with personal or family history of MTC or MEN 2
• Women with a history of pancreatitis, especially gallstone-related pancreatitis
• Women with severe gastroparesis (Rybelsus further slows gastric emptying)
• Women with a history of medullary thyroid cancer in a first-degree relative
• Women with type 1 diabetes (not an approved indication; DKA risk)

The PIONEER-4 Trial: What the Best Head-to-Head Data Show

The PIONEER-4 trial (Lancet, 2019) remains the most cited head-to-head comparison for oral semaglutide, pitting 14 mg oral semaglutide against 1.2 mg injectable liraglutide and placebo over 52 weeks in 711 adults with type 2 diabetes. The headline result: oral semaglutide reduced HbA1c by 1.2 percentage points vs. 1.1 percentage points for liraglutide (non-inferior). Body weight fell by 4.4 kg on oral semaglutide vs. 3.1 kg on liraglutide.

A limitation relevant to women: the trial did not report outcomes stratified by sex or hormonal status. Approximately 51% of participants were women, but no sex-disaggregated efficacy or safety subgroup appeared in the primary publication. This is the kind of reporting gap the NIH's Sex as a Biological Variable (SABV) policy was designed to address, and it is still routinely ignored in diabetes trials.

EMA and International Post-Market Signals

The European Medicines Agency's EPAR for Rybelsus aligns broadly with the FDA label but adds a requirement for annual benefit-risk reassessment for the thyroid C-cell signal. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has not issued additional restrictions beyond those on the FDA label as of early 2025. The EMA EPAR does note that reports of hair loss (telogen effluvium secondary to rapid weight loss) have emerged in the class-wide semaglutide signal, which is of particular concern for women given the overlap with female pattern hair loss and the hair-cycle disruption that occurs naturally during perimenopause.

Practical Guidance: Monitoring for Women on Rybelsus

Based on the FAERS signal profile and the label's warnings, here is a life-stage-aware monitoring framework for women on Rybelsus.

Reproductive-Age Women (18-45)

• Confirm reliable contraception before prescribing.
• Review oral contraceptive timing (1 hour before or 4 hours after Rybelsus).
• Monitor menstrual cycle changes at each visit; report any cycle irregularity, as PCOS-related hyperandrogenism may improve or unmask new thyroid pathology.
• Baseline and 6-month lipase if personal pancreatitis history exists.
• HbA1c every 3 months until target; then every 6 months.

Perimenopausal Women (Typically 45-55)

• GI symptom assessment should acknowledge the luteal-phase amplification of nausea, which may diminish as cycles become irregular.
• Screen for gallstones with abdominal ultrasound before initiation if symptomatic, given the elevated gallstone risk in this demographic.
• Thyroid function annually; calcitonin only if clinically indicated.

Post-Menopausal Women

• GI tolerability often improves. If GI symptoms are severe in a post-menopausal woman, reconsider gastroparesis or autonomic neuropathy before attributing symptoms to the drug.
• Bone density surveillance is relevant because rapid weight loss on any GLP-1 agent may reduce mechanical loading on bone. Dual-energy X-ray absorptiometry (DXA) per standard guidelines.
• Retinal exam annually for women with longstanding diabetes.